UK health technology assessment body NICE has published draft guidance rejecting bluebird bio’s gene therapy Zynteglo for routine funding on the National Health Service. The decision making behind the guidance sends a negative signal to investors in gene therapies, warns the company.
Bluebird was “shocked and disappointed by the recommendations,” said Nicola Redfern, bluebird’s UK General Manager.








